Top

Acta Neurochirurgica

Published in:

01-01-2013 | Letter to the editor

Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial

Authors: Colin Watts, Laurence Dunn, Keyoumars Ashkan, Michael Jenkinson, Paul Smith

Published in: Acta Neurochirurgica | Issue 1/2013

Excerpt

Dear Editor, …

d’Avella D, Dellapuppa A (2012) Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomas. Acta Neurochir (Wien) 154:1379–1381CrossRef

De Bonis P, Anile C, Pompucci A, Fiorentino A, Balducci M, Chiesa S, Maira G, Mangiola A (2012) Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien) 154:1371–1378CrossRef

Price SJ, Whittle IR, Ashkan K, Grundy P, Cruickshank G (2012) NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice. Br J Neurosurg 26:331–335PubMedCrossRef

Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMed

Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

Nuno M, Mukherjee D, Carico C, Elramsisy A, Veeravagu A, Black KL, Patil CG (2012) The effect of centralization of caseload for primary brain tumor surgeries: trends from 2001–2007. Acta Neurochir (Wien) 154:1343–1350CrossRef

Guilfoyle MR, Weerakkody RA, Oswal A, Oberg I, Jeffery C, Haynes K, Kullar PJ, Greenberg D, Jefferies SJ, Harris F, Price SJ, Thomson S, Watts C (2011) Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme. Br J Cancer 104:1810–1815PubMedCrossRef

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401PubMedCrossRef

Title: Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial
Authors: Colin Watts
Laurence Dunn
Keyoumars Ashkan
Michael Jenkinson
Paul Smith
Publication date: 01-01-2013
Publisher: Springer Vienna
Published in: Acta Neurochirurgica / Issue 1/2013
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-012-1533-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2013

Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival

Clinical outcomes of tuberculum sellae meningiomas focusing on reversibility of postoperative visual function

Effect of systemic celecoxib on human meningioma after intracranial transplantation into nude mice

Calcifying pseudoneoplasms of the neuraxis (CAPNON): clinical features and therapeutic options

Decompressive craniectomy for acute subdural hematomas: time for a randomized trial

Letter to the editor: decompressive craniectomy for acute subdural hematoma